DGAP-News: curasan AG

DGAP-News: curasan signs marketing agreement with Silony Medical International

DGAP-News: curasan AG / Key word(s): Alliance curasan signs marketing agreement with Silony Medical International

24.05.2016 / 09:51 The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

- Outlicensing of CERACELL Ortho for distribution in Europe

- First marketing agreement to increase utilization of production capacity at the Frankfurt site

- Further expansion of access to the orthopedics market

curasan AG (ISIN DE0005494538), a leading specialist for medical products in the orthobiologics sector, has signed a marketing agreement with Silony Medical International AG concerning its synthetic bone grafting material CERACELL Ortho.

The company based in Frauenfeld, Switzerland, immediately receives the distribution rights in the orthopedics sector for CERACELL Ortho in the DACH region, Benelux, and further selected European countries. Moreover, the agreement also grants the company the right to market CERACELL Ortho as a private label in the future.

Silony specializes in the orthopedic clinic market and produces implant and instrument systems used in spinal surgery and endoprosthesis. The distribution rights encompass Germany, Switzerland, Great Britain, Italy, Austria, Czech Republic and Benelux. The exclusive marketing of CERACELL Ortho by Silony is an optimal addition to the established sales range of the company in these territories.

"Part of our strategy is to make better use of the capacity provided by our state-of-the-art production lines at the Frankfurt site to increase customer access to our established and new product", emphasizes Michael Schlenk, CEO of curasan AG. "With CERACELL Ortho, Silony can now offer a high-quality, new product in the attractive orthopedics market. At the same time, curasan profits from a higher utilization of production capacity and additional revenues and earnings contributions. It is a classic win-win situation."

Marcus Kerwin, Managing Director of Silony Medical International AG, considers the cooperation with curasan AG to be an ideal enrichment of the company. "CERACELL Ortho fits perfectly with our own product line. By offering this modern bone grafting material, we can put together a comprehensive and attractive package for bone surgery and respond to hospital demand by supplying from a single source. The product launch shall take place in the near future."

For the current fiscal year 2016, curasan expects additional revenues of over 0.1 million euros as a result of the marketing agreement. The company assumes that revenues and earning contributions shall be over twice that amount starting in 2017. In the revenues and earnings forecast issued this year on April 28, this sales volume growth was already taken into consideration for 2016.

About curasan AG:

curasan AG develops, manufactures and markets biomaterials and other medical products in the field of bone and tissue regeneration. A pioneer in its industry, curasan is specialized primarily on synthetic bone grafting materials for dental and orthopedic applications. Numerous patents and a comprehensive list of scientific documentation prove the clinical success of the products and the highly innovative strength of curasan. Surgically active dentists, implantologists and oral, maxillary surgeons, as well as orthopedics, traumatologists and spine surgeons worldwide benefit from the broad range of the premium quality highly innovation product portfolio. curasan maintains its own high-tech facilities for research, development and manufacturing in Frankfurt/Main, Germany, which are approved by the Food and Drug Administration (FDA) and other international authorities. In addition to its headquarters, the company has a subsidiary, curasan Inc., in the Research Triangle Park, near Raleigh, N.C., USA. The shares of curasan AG are listed in the General Standard at the Frankfurt Stock Exchange.

About Silony Medical International AG:

Silony is specialized in the orthopedic clinic market. The products and achievements from Silony are precisely customized to the needs of patients, doctors and OR nursing staff in hospitals. In the field of spinal fixation and endoprosthesis, the company develops and produces implants and instruments as living systems. The joint system development with experienced surgeons and specialists from surgical and sterilization wards results in consistently well-conceived, modular, and versatile products.

About CERACELL Ortho

CERACELL Ortho is a synthetic, biocompatible ceramic material made out of a resorbable, silicated beta-tricalcium phosphate matrix. The product is provided as granules and foam in different forms. It is implanted for filling, bridging and reconstructing bone defects as well as for bone fusion.



Contact: Ingo Middelmenne Head of Investor Relations Tel. +49 6027 40900-45 Fax +49 6027 40900-39 ingo.middelmenne@curasan.de

Andrea Weidner Head of Corporate Communications Tel. +49 6027 40900-51 Fax +49 6027 40900-39 andrea.weidner@curasan.de www.curasan.de

---------------------------------------------------------------------------

24.05.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

---------------------------------------------------------------------------

Language: English Company: curasan AG Lindigstraße 4 63801 Kleinostheim Germany Phone: 06027/40 900 0 Fax: 06027/40 900 29 E-mail: info@curasan.de Internet: www.curasan.de ISIN: DE0005494538 WKN: 549453 Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart End of News DGAP News Service ---------------------------------------------------------------------------

466079 24.05.2016